Cargando…

Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials

INTRODUCTION: Subcutaneous (SC) injection is a common route of drug administration; however, injection site pain (ISP) might create a negative patient experience. We evaluated ISP, bioequivalence, and overall safety of the citrate-free (CF) formulation of ixekizumab, a high-affinity monoclonal antib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chabra, Sanjay, Gill, B. J., Gallo, Gaia, Zhu, Danting, Pitou, Celine, Payne, Christopher D., Accioly, Ana, Puig, Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022732/ https://www.ncbi.nlm.nih.gov/pubmed/35449322 http://dx.doi.org/10.1007/s12325-022-02126-0

Ejemplares similares

Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure
por: Griffiths, Christopher E. M., et al.
Publicado: (2022)

Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
por: Deodhar, Atul A, et al.
Publicado: (2022)

Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)
por: Jackson, Kimberley, et al.
Publicado: (2021)

Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis
por: Gladman, Dafna D., et al.
Publicado: (2019)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Kirkham, Bruce W., et al.
Publicado: (2023)

Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3
por: EGEBERG, Alexander, et al.
Publicado: (2022)

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
por: Armstrong, April, et al.
Publicado: (2019)

Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis
por: Combe, Bernard, et al.
Publicado: (2020)

Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States
por: Bergman, Martin, et al.
Publicado: (2020)

A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
por: Wasel, Norman, et al.
Publicado: (2020)

Ixekizumab-induced alopecia areata
por: Eldirany, Sherif A., et al.
Publicado: (2019)

Acrodermatitis continua of Hallopeau successfully treated with ixekizumab: A case report
por: Battista, Teresa, et al.
Publicado: (2022)

Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis
por: Tomelleri, Alessandro, et al.
Publicado: (2022)

Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Elewski, Boni E., et al.
Publicado: (2022)

Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging
por: Maksymowych, Walter P, et al.
Publicado: (2022)

Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
por: Egeberg, Alexander, et al.
Publicado: (2023)

Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection
por: Miller, John, et al.
Publicado: (2021)

Erythrodermic psoriasis after discontinuation of ixekizumab
por: Potter, Kathryn Anne, et al.
Publicado: (2017)

Pyoderma gangrenosum in a patient on ixekizumab
por: Pollack, Ilana R., et al.
Publicado: (2021)

Ixekizumab‐induced urticarial drug eruption
por: Kaneoka, Ayaka, et al.
Publicado: (2023)

Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double‐Blind Withdrawal Study
por: Coates, Laura C., et al.
Publicado: (2021)

Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
por: Egeberg, Alexander, et al.
Publicado: (2023)

Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
por: Smolen, Josef S., et al.
Publicado: (2020)

Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials
por: Eder, Lihi, et al.
Publicado: (2022)

Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)
por: Chandran, Vinod, et al.
Publicado: (2020)

Changes in Patient Reported Pain Measures With the Citrate-free Adalimumab Formulation in Pediatric Inflammatory Bowel Disease Patients
por: Patel, Ashish S., et al.
Publicado: (2020)

Successful Treatment of Pityriasis Rubra Pilaris with Ixekizumab
por: Hanfstingl, Kathrin, et al.
Publicado: (2018)

Toxoplasmosis in a patient receiving ixekizumab for psoriasis
por: Lobo, Yolanka, et al.
Publicado: (2020)

Ixekizumab May Improve Renal Function in Psoriasis
por: Amoruso, Giuseppe Fabrizio, et al.
Publicado: (2021)

The role of ixekizumab in non-radiographic axial spondyloarthritis
por: San Koo, Bon, et al.
Publicado: (2021)

Onset of vitiligo in a psoriasis patient on ixekizumab
por: Marasca, Claudio, et al.
Publicado: (2021)

Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis
por: Mease, Philip, et al.
Publicado: (2019)

Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis
por: PAPP, Kim, et al.
Publicado: (2022)

Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)
por: Orbai, Ana-Maria, et al.
Publicado: (2020)

Formulation and Evaluation of Licorice Shampoo in Comparison with Commercial Shampoo
por: Azadbakht, Mohammad, et al.
Publicado: (2018)

Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
por: Braun, Jürgen, et al.
Publicado: (2022)

Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial
por: Deodhar, Atul, et al.
Publicado: (2020)

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study
por: Lebwohl, M.G., et al.
Publicado: (2019)

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jleoo4gdt4ou1auc3t5iahtk4d